AXL and ovarian carcinoma: Developed as a non-selective TKI that inhibits multiple RTKs, including MET, AXL, VEGFR2, RET, KIT, and ROS1 [205], and the related angiogenesis and metastasis processes [206, 207], cabozantinib has shown vast in vitro antitumour activity in extensive studies on human umbilical vein endothelial cells (HUVECs) and RCC, HCC, medullary thyroid cancer, and ovarian cancer cells [148, 208–214].